At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 58 enrolled
Drug / intervention
SER-287 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
In Brief
A Phase 1 clinical trial evaluating SER-287, Placebo, and 2 other interventions for Ulcerative Colitis. Completed, enrolled 58 participants across 1 site.
Detailed Summary
A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJan 2016
Primary CompletionDec 2017
Study CompletionJan 2018
TodayJul 2026
First PostedDec 1, 2015
Enrollment StartJan 13, 2016
Primary CompletionDec 6, 2017
Study CompletionJan 26, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.6 years ago
Interventions
SER-287drug
Placebodrug
Placebo Pre-Treatdrug
Vancomycin Pre-Treatdrug